Commercialization

As of April 2016, the Stem Cell Network’s catalyst of commercialization of stem cell research has led to 570 patent applications, 93 issued patents, 60+ licenses granted, the growth or launch of 11 start-up biotechnology companies and the establishment of a new Centre for the Commercialization of Regenerative Medicine (CCRM) to develop a strong industry presence in several emerging technology areas likely to be crucial to the future delivery of stem cell-based therapies.

story_commercialzation-1Part of the Stem Cell Network’s mandate was to support the commercialization of its funded research, and by extension to act as a catalyst for commercialization across the whole Canadian stem cell research sector. The Network actively worked to ensure the research of its members was given every opportunity to move forward into product development by making targeted investments in commercialization-focused research grants, supporting opportunities and partnerships and offering resources to assist in product development.

story_commercialzation-2

In 2005, the Network re-aligned its research program to conform to the main routes to market and to ensure that all projects clearly iterated key deliverables, milestones and outcomes within the context of individual product development strategies. SCN also provided financial support for IP filing, commercialization impact grants to support commercially relevant proof-of-principle studies and, upon request, access to product development and IP expertise.

The Network’s research and commercialization investments have directly resulted in 570 patent applications, 93 issued patents, 60+ licenses granted and the growth or launch of 11 start-up biotechnology companies among Network researchers. SCN also worked fostered the development of the Centre for Commercialization of Regenerative Medicine (CCRM), an organization that carries forward the lasting legacy of SCN to develop a strong industry presence in several emerging technology areas likely to be crucial to the future delivery of stem cell-based therapies.

Impacts

  • Establishment of the Centre for Commercialization of Regenerative Medicine in 2011
  • Development of a standardized IP toolkit for technology transfer
  • 570 patent applications resulting from SCN research investments

  • 93 issued patents resulting from SCN research investments
  • 60+ licenses granted resulting from SCN research investments
  • 11 start-up biotechnology companies launched or grown through SCN research investments

Related Content

  • 2008-09 Annual Report, p. 12
  • 2009-10 Annual Report, p. 11
  • 2011-12 Annual Report, p. 12